Back to Search Start Over

Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis.

Authors :
Fassan M
Dall'Olmo L
Galasso M
Braconi C
Pizzi M
Realdon S
Volinia S
Valeri N
Gasparini P
Baffa R
Souza RF
Vicentini C
D'Angelo E
Bornschein J
Nuovo GJ
Zaninotto G
Croce CM
Rugge M
Source :
Oncotarget [Oncotarget] 2014 Aug 30; Vol. 5 (16), pp. 7162-71.
Publication Year :
2014

Abstract

Barrett's esophagus (BE) involves a metaplastic replacement of native esophageal squamous epithelium (Sq) by columnar-intestinalized mucosa, and it is the main risk factor for Barrett-related adenocarcinoma (BAc). Ultra-conserved regions (UCRs) are a class non-coding sequences that are conserved in humans, mice and rats. More than 90% of UCRs are transcribed (T-UCRs) in normal tissues, and are altered at transcriptional level in tumorigenesis. To identify the T-UCR profiles that are dysregulated in Barrett's mucosa transformation, microarray analysis was performed on a discovery set of 51 macro-dissected samples obtained from 14 long-segment BE patients. Results were validated in an independent series of esophageal biopsy/surgery specimens and in two murine models of Barrett's esophagus (i.e. esophagogastric-duodenal anastomosis). Progression from normal to BE to adenocarcinoma was each associated with specific and mutually exclusive T-UCR signatures that included up-regulation of uc.58-, uc.202-, uc.207-, and uc.223- and down-regulation of uc.214+. A 9 T-UCR signature characterized BE versus Sq (with the down-regulation of uc.161-, uc.165-, and uc.327-, and the up-regulation of uc.153-, uc.158-, uc.206-, uc.274-, uc.472-, and uc.473-). Analogous BE-specific T-UCR profiles were shared by human and murine lesions. This study is the first demonstration of a role for T-UCRs in the transformation of Barrett's mucosa.

Details

Language :
English
ISSN :
1949-2553
Volume :
5
Issue :
16
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
25216530
Full Text :
https://doi.org/10.18632/oncotarget.2249